Verbrugge I, de Vries E, Tait S W G, Wissink E H J, Walczak H, Verheij M, Borst J
Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Oncogene. 2008 Jan 24;27(5):574-84. doi: 10.1038/sj.onc.1210696. Epub 2007 Aug 6.
In many tumor cell types, ionizing radiation (IR) or DNA-damaging anticancer drugs enhance sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis, which is of great clinical interest. We have investigated the molecular mechanism underlying the response to combined modality treatment in p53-mutant Jurkat T leukemic cells overexpressing Bcl-2. These cells are largely resistant to individual treatment with TRAIL or IR, but sensitive to combined treatment, in vitro as well as in vivo. We demonstrate that IR and DNA-damaging anticancer drugs enable TRAIL receptor-2 and CD95/Fas to bypass the mitochondrial pathway for effector caspase activation. This was validated by RNA interference for Bax and Bak and by overexpression of dominant-negative Caspase-9. Improved effector caspase activation was neither caused by altered expression of proapoptotic components nor by impaired activity of inhibitor of apoptosis proteins or nuclear factor-kappaB signaling. Rather, we found that pretreatment of cells with IR caused quantitative and qualitative changes in death receptor signaling. It strongly improved the capacity of ligand-bound receptors to recruit FADD and activate Caspase-8 and -10 in the death-inducing signaling complex, while c-FLIP(L) levels were unaffected.
在许多肿瘤细胞类型中,电离辐射(IR)或DNA损伤性抗癌药物可增强肿瘤坏死因子相关凋亡诱导配体(TRAIL)诱导的凋亡敏感性,这具有重大临床意义。我们研究了过表达Bcl-2的p53突变型Jurkat T白血病细胞对联合治疗反应的分子机制。这些细胞对TRAIL或IR单独治疗具有很大抗性,但对体外和体内联合治疗敏感。我们证明,IR和DNA损伤性抗癌药物使TRAIL受体2和CD95/Fas能够绕过线粒体途径激活效应半胱天冬酶。这通过对Bax和Bak的RNA干扰以及显性负性Caspase-9的过表达得到验证。效应半胱天冬酶激活的改善既不是由促凋亡成分表达改变引起的,也不是由凋亡蛋白抑制剂或核因子-κB信号传导活性受损引起的。相反,我们发现用IR预处理细胞会导致死亡受体信号传导发生定量和定性变化。它极大地提高了配体结合受体在死亡诱导信号复合物中募集FADD并激活Caspase-8和 -10的能力,而c-FLIP(L)水平不受影响。